Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARCY J FLECKER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1508875774
CMS profile
691345
Location
SMITHFIELD, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,344.27

228 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,344.27 228

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARCY J FLECKER

NPI 1508875774 · CMS profile ID 691345

Allopathic & Osteopathic Physicians / Family Medicine

SMITHFIELD, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARCY J FLECKER, NPI 1508875774, CMS profile ID 691345. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARCY J FLECKER, NPI 1508875774, CMS profile ID 691345. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARCY J FLECKER, NPI 1508875774, CMS profile ID 691345, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

228 matching records · $3,344.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 228 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 228.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Hikma Pharmaceuticals USA $14.3306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 808542443 CMS
AbbVie Inc. $9.8206/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794480419 CMS
Novo Nordisk Inc $17.5506/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811690431 CMS
RedHill Biopharma Inc. $13.3306/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799921433 CMS
GlaxoSmithKline, LLC. $13.1006/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802291181 CMS
Astellas Pharma US Inc $17.0506/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821321851 CMS
Novo Nordisk Inc $16.0906/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811137886 CMS
Janssen Pharmaceuticals, Inc $12.6706/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331727 CMS
AstraZeneca Pharmaceuticals LP $15.6706/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829498427 CMS
Amarin Pharma Inc. $20.8206/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815107055 CMS
Lilly USA, LLC $8.6506/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818585465 CMS
Biohaven Pharmaceuticals, Inc. $14.0106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491113 CMS
Ironwood Pharmaceuticals, Inc $19.6506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855109675 CMS
Novo Nordisk Inc $19.6106/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810638069 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.2306/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819926739 CMS
GlaxoSmithKline, LLC. $13.5106/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802741969 CMS
Janssen Pharmaceuticals, Inc $10.6606/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331745 CMS
Novo Nordisk Inc $17.1206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810767083 CMS
PFIZER INC. $17.4706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833496475 CMS
Biohaven Pharmaceuticals, Inc. $5.2806/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491111 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.5606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763450632 CMS
AbbVie Inc. $7.7805/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794480415 CMS
Novo Nordisk Inc $15.0805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811442711 CMS
Novo Nordisk Inc $15.0805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811690427 CMS
AbbVie Inc. $13.6405/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794480411 CMS
AstraZeneca Pharmaceuticals LP $13.7505/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829710693 CMS
GlaxoSmithKline, LLC. $13.0905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801577131 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.3005/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850413085 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.1105/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819926737 CMS
RedHill Biopharma Inc. $17.4605/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 799921431 CMS
Janssen Pharmaceuticals, Inc $12.6705/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331747 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.6005/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763450634 CMS
Ironwood Pharmaceuticals, Inc $19.3405/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855109673 CMS
Teva Pharmaceuticals USA, Inc. $23.4805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839714845 CMS
Amarin Pharma Inc. $16.4905/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815107065 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.3805/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763789152 CMS
Lilly USA, LLC $19.7205/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818585463 CMS
PFIZER INC. $16.3805/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833464209 CMS
AbbVie Inc. $4.7005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794480407 CMS
Lilly USA, LLC $16.4405/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818632393 CMS
Biohaven Pharmaceuticals, Inc. $12.4805/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491109 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.6505/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763450636 CMS
GlaxoSmithKline, LLC. $12.3905/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803083801 CMS
AbbVie Inc. $20.8005/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794480403 CMS
Amarin Pharma Inc. $18.5004/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815113567 CMS
GlaxoSmithKline, LLC. $8.0304/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802697922 CMS
GlaxoSmithKline, LLC. $7.6204/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802855425 CMS
Novo Nordisk Inc $16.7904/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810638065 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6904/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819926735 CMS
AbbVie Inc. $18.9904/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794480399 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,655.12 198
PY2020 $2,847.46 217
PY2021 $3,344.27 228
PY2022 $2,733.92 177
PY2023 $3,486.03 207
PY2024 $2,942.34 185
PY2025 $2,201.75 132

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,361,760.66 151
PY2024 Principal investigator $1,248,049.16 184
PY2023 Principal investigator $1,661,032.99 154
PY2022 Recipient $1,240.00 1
PY2022 Principal investigator $624,324.25 141
PY2021 Recipient $4,735.66 1
PY2021 Principal investigator $455,969.90 140
PY2020 Principal investigator $640,013.50 180
PY2019 Principal investigator $912,016.56 121

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

151 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $715.76 12/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202532428
Principal investigator 1 ABBVIE INC. $582.00 12/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202532430
Principal investigator 1 ABBVIE INC. $772.50 12/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) with a 24-week Open-label Treatment Extension No dispute reported 06/30/2026 1202533543
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202533735
Principal investigator 1 Genentech, Inc. $3,500.00 12/24/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607750
Principal investigator 1 Genentech, Inc. $450.00 12/24/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607758
Principal investigator 1 ABBVIE INC. $2,631.55 12/18/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202531294
Principal investigator 1 PFIZER INC. $17,861.87 12/17/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228744172
Principal investigator 1 PFIZER INC. $21,361.06 12/16/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228748969
Principal investigator 1 Genentech, Inc. $3,000.00 12/15/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1211607313
Principal investigator 1 ABBVIE INC. $330.75 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202530186
Principal investigator 1 ABBVIE INC. $2,854.58 12/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202530190
Principal investigator 1 ABBVIE INC. $820.00 12/10/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202529880
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,635.00 12/10/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185548659
Principal investigator 1 OraSure Technologies Inc. $520.00 12/05/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792142
Principal investigator 1 OraSure Technologies Inc. $250.00 12/05/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792144
Principal investigator 1 OraSure Technologies Inc. $500.00 12/05/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792146
Principal investigator 1 OraSure Technologies Inc. $1,150.00 12/05/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792198
Principal investigator 1 ABBVIE INC. $3,090.00 12/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202528342
Principal investigator 1 ABBVIE INC. $263.25 12/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202528344
Principal investigator 1 ABBVIE INC. $2,000.00 12/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202528364
Principal investigator 1 Ardelyx, Inc. $2,353.75 12/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838864
Principal investigator 1 Genentech, Inc. $35,002.00 12/01/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607754
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,027.22 11/21/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185548653
Principal investigator 1 OraSure Technologies Inc. $1,000.00 11/21/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792194
Principal investigator 1 OraSure Technologies Inc. $400.00 11/21/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792196
Principal investigator 1 PFIZER INC. $148.60 11/13/2025 Non-covered Recipient Entity
Frontier Clinical Res LLC
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228719523
Principal investigator 1 PFIZER INC. $117.00 11/13/2025 Non-covered Recipient Entity
Frontier Clinical Res LLC
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228723908
Principal investigator 1 PFIZER INC. $5,143.50 11/13/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228737493
Principal investigator 1 Ardelyx, Inc. $923.25 11/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838820
Principal investigator 1 OraSure Technologies Inc. $3,000.00 11/07/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792192
Principal investigator 1 ABBVIE INC. $3,090.00 11/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202521327
Principal investigator 1 PFIZER INC. $5,975.45 11/05/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228737481
Principal investigator 1 Ardelyx, Inc. $1,555.25 11/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838779
Principal investigator 1 Ardelyx, Inc. $715.25 11/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838786
Principal investigator 1 OraSure Technologies Inc. $360.00 10/31/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792190
Principal investigator 1 ABBVIE INC. $2,976.75 10/28/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202518809
Principal investigator 1 Eli Lilly and Company $3,251.37 10/28/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) No dispute reported 06/30/2026 1187881758
Principal investigator 1 Novartis Pharmaceuticals Corporation $182,872.75 10/27/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310494
Principal investigator 1 ABBVIE INC. $850.00 10/23/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202518381
Principal investigator 1 PFIZER INC. $1,279.80 10/22/2025 Non-covered Recipient Entity
Frontier Clinical Research
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 No dispute reported 06/30/2026 1228723078
Principal investigator 1 ABBVIE INC. $3,334.62 10/16/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202517299
Principal investigator 1 OraSure Technologies Inc. $6,000.00 10/10/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792124
Principal investigator 1 OraSure Technologies Inc. $1,020.00 10/10/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792162
Principal investigator 1 ABBVIE INC. $5,085.00 10/09/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202515851
Principal investigator 1 Ardelyx, Inc. $923.25 10/08/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838643
Principal investigator 1 Ardelyx, Inc. $437.50 10/08/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838646
Principal investigator 1 Eli Lilly and Company $720.00 10/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187882426
Principal investigator 1 Eli Lilly and Company $219,172.00 09/29/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187882424
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,475.25 09/17/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185548655
Principal investigator 1 ABBVIE INC. $2,933.75 09/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202510688
Principal investigator 1 ABBVIE INC. $124.75 09/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202510690
Principal investigator 1 ABBVIE INC. $2,900.00 09/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202510692
Principal investigator 1 ABBVIE INC. $1,090.58 09/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202510694
Principal investigator 1 Ardelyx, Inc. $1,650.25 09/08/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838593
Principal investigator 1 ABBVIE INC. $2,900.00 09/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202510178
Principal investigator 1 ABBVIE INC. $2,970.00 09/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202509244
Principal investigator 1 ABBVIE INC. $2,900.00 09/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202509246
Principal investigator 1 Ardelyx, Inc. $840.25 09/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838583
Principal investigator 1 Ardelyx, Inc. $1,370.25 08/18/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838561
Principal investigator 1 GlaxoSmithKline, LLC. $7,054.03 08/15/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192110795
Principal investigator 1 OraSure Technologies Inc. $4,500.00 08/08/2025 Non-covered Recipient Entity
Frontier Clinical Research
Clinical Sample Collection and Testing Protocol No dispute reported 06/30/2026 1248792090
Principal investigator 1 AstraZeneca Pharmaceuticals LP $85,387.90 08/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185548657
Principal investigator 1 ABBVIE INC. $5,670.00 08/06/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202502598
Principal investigator 1 Ardelyx, Inc. $930.25 08/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838510
Principal investigator 1 Ardelyx, Inc. $875.00 08/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838514
Principal investigator 1 ABBVIE INC. $3,817.62 07/24/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202499648
Principal investigator 1 PFIZER INC. $393.53 07/11/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228789933
Principal investigator 1 ABBVIE INC. $1,750.00 07/08/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202497378
Principal investigator 1 ABBVIE INC. $2,970.00 07/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202496211
Principal investigator 1 Genentech, Inc. $9,298.00 07/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607673
Principal investigator 1 Ardelyx, Inc. $1,370.25 07/01/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838442
Principal investigator 1 Eli Lilly and Company $352.48 06/24/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187883730
Principal investigator 1 Genentech, Inc. $6,860.00 06/23/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607627
Principal investigator 1 PFIZER INC. $8,868.23 06/21/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228775796
Principal investigator 1 GlaxoSmithKline, LLC. $3,396.40 06/18/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172419
Principal investigator 1 Ardelyx, Inc. $715.25 06/09/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838405
Principal investigator 1 PFIZER INC. $21,516.41 06/06/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228722712
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,025.00 06/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185548663
Principal investigator 1 Genentech, Inc. $2,596.00 05/28/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607584
Principal investigator 1 ABBVIE INC. $587.23 05/22/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202485779
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $8,892.21 05/19/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187882428
Principal investigator 1 Ardelyx, Inc. $1,500.00 05/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838361
Principal investigator 1 ABBVIE INC. $4,400.00 05/08/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202484297
Principal investigator 1 ABBVIE INC. $16,450.00 05/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202482487
Principal investigator 1 Genentech, Inc. $1,298.00 05/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607571
Principal investigator 1 Genentech, Inc. $5,000.00 05/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607592
Principal investigator 1 GlaxoSmithKline, LLC. $896.00 05/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192170348
Principal investigator 1 GlaxoSmithKline, LLC. $1,286.60 05/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172391
Principal investigator 1 ABBVIE INC. $2,650.05 05/06/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481383
Principal investigator 1 Ardelyx, Inc. $3,089.00 05/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838333
Principal investigator 1 Ardelyx, Inc. $965.25 05/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838345
Principal investigator 1 Genentech, Inc. $2,487.90 04/29/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1211607302
Principal investigator 1 PFIZER INC. $64,791.92 04/29/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228779378
Principal investigator 1 Genentech, Inc. $5,192.00 04/25/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607575
Principal investigator 1 Genentech, Inc. $29,204.00 04/25/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607588
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 04/23/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172404
Principal investigator 1 GlaxoSmithKline, LLC. $937.50 04/23/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172415
Principal investigator 1 Genentech, Inc. $3,000.00 04/21/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1211607297
Principal investigator 1 PFIZER INC. $86.34 04/15/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228770186
Principal investigator 1 OraSure Technologies Inc. $1,750.00 04/14/2025 Non-covered Recipient Entity
Frontier Clinical Research
Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use No dispute reported 06/30/2026 1248792236
Principal investigator 1 Genentech, Inc. $1,298.00 04/11/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607619
Principal investigator 1 PFIZER INC. $37,145.25 04/10/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228794073
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 04/09/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172396
Principal investigator 1 GlaxoSmithKline, LLC. $4,500.00 04/09/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172400
Principal investigator 1 GlaxoSmithKline, LLC. $625.00 04/09/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172413
Principal investigator 1 Ardelyx, Inc. $2,423.25 04/08/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838241
Principal investigator 1 Genentech, Inc. $2,596.00 04/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607633
Principal investigator 1 GlaxoSmithKline, LLC. $3,445.20 04/04/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192170357
Principal investigator 1 ABBVIE INC. $472.50 04/03/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202471748
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,150.00 04/02/2025 Non-covered Recipient Entity
LONG ISLAND REGIONAL ARTHRITIS AND OSTEOPOROSIS CARE, PC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185548661
Principal investigator 1 Genentech, Inc. $2,596.00 04/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607562
Principal investigator 1 ABBVIE INC. $1,250.00 04/01/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202467878
Principal investigator 1 PFIZER INC. $1,456.65 04/01/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228797167
Principal investigator 1 Novartis Pharmaceuticals Corporation $54,147.18 03/31/2025 Non-covered Recipient Entity
MONTGOMERY MEDICAL
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190304221
Principal investigator 1 OraSure Technologies Inc. $950.00 03/31/2025 Non-covered Recipient Entity
Frontier Clinical Research
Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use No dispute reported 06/30/2026 1248792206
Principal investigator 1 PFIZER INC. $125.38 03/28/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228775525
Principal investigator 1 ABBVIE INC. $675.00 03/27/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202466738
Principal investigator 1 Genentech, Inc. $7,644.00 03/26/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607441
Principal investigator 1 Eli Lilly and Company $14,922.00 03/25/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187882724
Principal investigator 1 Genentech, Inc. $9,086.00 03/21/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607411
Principal investigator 1 Genentech, Inc. $2,512.10 03/20/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1211607284
Principal investigator 1 PFIZER INC. $83.60 03/19/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228775432
Principal investigator 1 OraSure Technologies Inc. $82,850.00 03/12/2025 Non-covered Recipient Entity
Frontier Clinical Research
Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use No dispute reported 06/30/2026 1248792178
Principal investigator 1 ABBVIE INC. $16,250.00 03/07/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202460113
Principal investigator 1 ABBVIE INC. $3,581.55 03/06/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202457158
Principal investigator 1 Genentech, Inc. $11,682.00 03/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607484
Principal investigator 1 Genentech, Inc. $7,726.00 02/19/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607458
Principal investigator 1 GlaxoSmithKline, LLC. $1,163.20 02/19/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192172408
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 02/14/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON No dispute reported 06/30/2026 1192170353
Principal investigator 1 Genentech, Inc. $1,303.00 02/12/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607504
Principal investigator 1 ABBVIE INC. $545.00 02/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202445216
Principal investigator 1 ABBVIE INC. $5,551.20 02/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202445219
Principal investigator 1 Genentech, Inc. $15,274.00 02/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607422
Principal investigator 1 Genentech, Inc. $7,783.00 02/05/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607501
Principal investigator 1 Ardelyx, Inc. $923.25 02/03/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838063
Principal investigator 1 Ardelyx, Inc. $887.50 02/03/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838066
Principal investigator 1 Ardelyx, Inc. $687.50 02/03/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD No dispute reported 06/30/2026 1247838070
Principal investigator 1 Eli Lilly and Company $756.52 01/31/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187883728
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,594.00 01/30/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310492
Principal investigator 1 Eli Lilly and Company $17,093.00 01/27/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187881660
Principal investigator 1 Genentech, Inc. $7,783.00 01/22/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607445
Principal investigator 1 Genentech, Inc. $90.00 01/17/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607437
Principal investigator 1 Genentech, Inc. $396.00 01/14/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607407
Principal investigator 1 Genentech, Inc. $192.00 01/14/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607453
Principal investigator 1 Genentech, Inc. $184.00 01/14/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211607493
Principal investigator 1 PFIZER INC. $1,574.12 01/09/2025 Non-covered Recipient Entity
Frontier Clinical Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228801527
Principal investigator 1 OraSure Technologies Inc. $3,750.00 01/08/2025 Non-covered Recipient Entity
Frontier Clinical Research
Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use No dispute reported 06/30/2026 1248792172
Principal investigator 1 OraSure Technologies Inc. $18,750.00 01/08/2025 Non-covered Recipient Entity
Frontier Clinical Research
Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use No dispute reported 06/30/2026 1248792176
Principal investigator 1 ABBVIE INC. $1,104.40 01/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1202435062
Principal investigator 1 ABBVIE INC. $2,180.25 01/02/2025 Non-covered Recipient Entity
FRONTIER CLINICAL RESEARCH LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202435134